Bill Details
Status
Latest action
2025-02-26 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Introduced Date
2025-02-26
Policy Area
Health
Committees
View committees (1)
Sponsors
Cosponsors
6
0
0
AI Summary This summary was generated by AI from the bill text. AI can get information wrong.
This bill would renew and expand a federal program that supports sickle cell disease care and research. It keeps the program going for the next several years, adds a stronger focus on preventing and treating complications from sickle cell disease, and gives the government more ways to fund outside groups that work on this issue. It also increases the amount of money available for the program and says Congress wants more research into the causes of inherited blood disorders and possible cures.
- It changes the program’s purpose so it covers both treatment of sickle cell disease and prevention and treatment of its complications.
- It allows the Department of Health and Human Services to make grants, not just contracts, and also use cooperative agreements with organizations doing this work.
- It raises the program’s funding to $8,205,000 each year from fiscal year 2025 through 2029, up from $4,455,000 a year in earlier years.
- It states that Congress wants more research to better understand inherited blood disorders, including sickle cell disease, and to find cures.
Official Summaries
No summaries available
Current Full Text
[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[S. 735 Introduced in Senate (IS)]
<DOC>
119th CONGRESS
1st Session
S. 735
To amend the Public Health Service Act to reauthorize a sickle cell
disease prevention and treatment demonstration program.
_______________________________________________________________________
IN THE SENATE OF THE UNITED STATES
February 26, 2025
Mr. Scott of South Carolina (for himself and Mr. Booker) introduced the
following bill; which was read twice and referred to the Committee on
Health, Education, Labor, and Pensions
_______________________________________________________________________
A BILL
To amend the Public Health Service Act to reauthorize a sickle cell
disease prevention and treatment demonstration program.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Sickle Cell Disease and Other
Heritable Blood Disorders Research, Surveillance, Prevention, and
Treatment Act of 2025''.
SEC. 2. SICKLE CELL DISEASE PREVENTION AND TREATMENT.
(a) In General.--Section 1106(b) of the Public Health Service Act
(42 U.S.C. 300b-5(b)) is amended--
(1) in paragraph (1)(A)(iii), by striking ``prevention and
treatment of sickle cell disease'' and inserting ``treatment of
sickle cell disease and the prevention and treatment of
complications of sickle cell disease'';
(2) in paragraph (2)(D), by striking ``prevention and
treatment of sickle cell disease'' and inserting ``treatment of
sickle cell disease and the prevention and treatment of
complications of sickle cell disease'';
(3) in paragraph (3)--
(A) in subparagraph (A), by striking ``enter into a
contract with'' and inserting ``make a grant to, or
enter into a contract or cooperative agreement with,'';
and
(B) in subparagraph (B), in each of clauses (ii)
and (iii), by striking ``prevention and treatment of
sickle cell disease'' and inserting ``treatment of
sickle cell disease and the prevention and treatment of
complications of sickle cell disease''; and
(4) in paragraph (6), by striking ``$4,455,000 for each of
fiscal years 2019 through 2023'' and inserting ``$8,205,000 for
each of fiscal years 2025 through 2029''.
(b) Sense of Congress.--It is the sense of Congress that further
research should be undertaken to expand the understanding of the causes
of, and to find cures for, heritable blood disorders, including sickle
cell disease.
<all>